Global Phage Therapy Market Strategic Research Report

The global phage therapy market occupies a pivotal position at the intersection of antimicrobial science, precision medicine, and mounting global health urgency. Valued at approximately USD 1.4 billion in 2024, the market is entering a period of accelerated clinical and commercial development driven by the escalating antimicrobial resistance (AMR) crisis, which the World Health Organization has designated one of the top ten global public health threats. Bacteriophages—viruses that selectively infect and destroy bacterial cells—represent a fundamentally distinct therapeutic modality from conventional antibiotics, offering targeted bacterial killing without the collateral disruption to commensal microbiota that characterizes broad-spectrum antibiotic use. This specificity, once considered a commercial liability, is now increasingly regarded as a clinical and regulatory asset as personalized medicine frameworks mature.

Three converging forces are shaping the market's commercial trajectory. First, the AMR burden continues to intensify: drug-resistant infections claimed an estimated 1.27 million attributable deaths globally in 2019, and projections suggest this figure could exceed 10 million annually by 2050 without intervention, creating an urgent unmet clinical need that phage therapy is uniquely positioned to address. Second, regulatory agencies including the U.S. FDA and the European Medicines Agency have begun establishing adaptive pathways—such as expanded access and magistral phage preparation frameworks in Belgium—that allow earlier patient access while clinical trial infrastructure matures, meaningfully reducing commercialization timelines. Third, growing public and private investment is funding phage biobank development, synthetic phage engineering, and combination phage-antibiotic formulations, which together expand the clinical indications addressable by licensed products. A meaningful restraint, however, remains the complexity of navigating regulatory frameworks that were architected for small-molecule drugs and are poorly suited to the biologically variable, patient-specific nature of many phage preparations, creating both approval uncertainty and manufacturing standardization challenges that elevate development costs.

This report delivers a comprehensive strategic analysis of the global phage therapy market across the 2025–2032 forecast period, covering market segmentation by phage type, therapeutic application, end-user setting, and delivery route, alongside granular regional and country-level forecasts. The study profiles ten leading companies, examines the competitive landscape, and provides scenario-based revenue projections calibrated to regulatory and clinical pipeline developments. It is designed for corporate strategy teams evaluating pipeline adjacencies, investment analysts assessing venture and public-market opportunities, M&A advisors benchmarking acquisition targets, and procurement managers planning infectious disease therapeutic sourcing.